{"id":67,"date":"2006-04-17T12:44:46","date_gmt":"2006-04-17T11:44:46","guid":{"rendered":"http:\/\/www.i-base.info\/qa\/?p=67"},"modified":"2021-11-22T12:19:07","modified_gmt":"2021-11-22T12:19:07","slug":"new-medications","status":"publish","type":"post","link":"https:\/\/i-base.info\/qa\/67","title":{"rendered":"New medications&#8230;"},"content":{"rendered":"<p>There are five new drugs or formulations that have either been approved        recently or are close to being approved, or are available in expanded access        programmes.<\/p>\n<ol>\n<li>Tipranavir was the most recent drug to be approved in Europe (in October        2005). Tipranavir is a protease inhibitor, which works against HIV that        is resistant to current protease inhibitors. It needs to be used with a        small boosting dose of ritonavir, like most other protease inhibitors. and        used in a combination with other drugs that are active.<\/li>\n<li>Darunavir (also called TMC-114) is likely to be approved later this year,        but is available now on expanded access. Darunavir is a protease inhibitor        that also works against HIV that is resistant to othe PIs.<\/li>\n<li>Kaletra is going to be replaced by a new formulation that requires fewer        pills, and which doesn<br \/>\n<\/li><\/ol>","protected":false},"excerpt":{"rendered":"<p>New medications &#8211; what are the new medications that will be available in the UK and the US?<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7,10,35],"tags":[],"class_list":["post-67","post","type-post","status-publish","format-standard","hentry","category-all-topics","category-changing-treatment","category-resistance"],"_links":{"self":[{"href":"https:\/\/i-base.info\/qa\/wp-json\/wp\/v2\/posts\/67","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/qa\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/qa\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/qa\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/qa\/wp-json\/wp\/v2\/comments?post=67"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/qa\/wp-json\/wp\/v2\/posts\/67\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/qa\/wp-json\/wp\/v2\/media?parent=67"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/qa\/wp-json\/wp\/v2\/categories?post=67"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/qa\/wp-json\/wp\/v2\/tags?post=67"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}